Clinical Trials Logo

Filter by:
NCT ID: NCT00820222 Completed - Metastases, Brain Clinical Trials

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer

Start date: April 14, 2009
Phase: Phase 3
Study type: Interventional

This open label study was designed to evaluate Lapatinib effect on incidence of brain metastases in ErbB2 (HER2) positive metastatic breast cancer patients exposed to prior taxanes or anthracyclines.

NCT ID: NCT00820079 Completed - Clinical trials for Gastroesophageal Reflux

ADX10059 as a Monotherapy in Patients With Gastroesophageal Reflux (GERD)

Start date: December 2008
Phase: Phase 2
Study type: Interventional

Evaluation of the effect of ADX10059 on symptom control in patients with gastroesophageal reflux.

NCT ID: NCT00819780 Completed - Colorectal Cancer Clinical Trials

PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors

Start date: April 24, 2009
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to estimate the treatment effect on progression-free survival (PFS) of panitumumab relative to bevacizumab in combination with mFOLFOX6 chemotherapy as first-line therapy in patients with tumors expressing wild-type KRAS, unresectable mCRC.

NCT ID: NCT00819585 Completed - Gout Clinical Trials

A Study of the Efficacy of Canakinumab in Prevention of Acute Flares in Chronic Gout Patients Initiating Allopurinol Therapy (Core Study) and a Long-term Study of the Efficacy and Safety of Canakinumab in Patients With Gout (Extension Study)

Start date: December 2008
Phase: Phase 2
Study type: Interventional

The 24-week, dose-ranging, multi-center, double-blind, double-dummy, active-controlled core study investigated the prophylactic effect of canakinumab on the signs and symptoms of acute flares in chronic gout patients initiating allopurinol therapy. The core study was followed by a 24-week open-label, multicenter extension study to assess the safety, tolerability, and efficacy of canakinumab in patients with gout who were given canakinumab at the time of gout flare.

NCT ID: NCT00819156 Completed - Prostate Cancer Clinical Trials

Dose Finding Trial With a New Treatment (Degarelix) for Prostate Cancer

Start date: February 2004
Phase: Phase 2
Study type: Interventional

The purpose of the trial was to evaluate the safety and efficacy of degarelix when comparing six different doses. The patients participating in the trial were treated with degarelix every month for a year. During the treatment the patients had to visit the clinic for investigations. Blood samples for testosterone, dihydrotestosterone, luteinizing hormone, follicle stimulating hormone, and Prostate Specific Antigen were taken and analysed throughout the trial.

NCT ID: NCT00817141 Completed - Clinical trials for Urinary Complications

Urinary Catheter and Fast-track Surgery

Start date: March 2008
Phase: N/A
Study type: Observational

Urinary catheter was placed during several days after colonic surgery. Nevertheless, it is probably unnecessary after Fast-Track colonic surgery. No prospective data permit to confirm it.

NCT ID: NCT00816153 Completed - Fluid Management Clinical Trials

Pleth Variability Index and Fluid Management During Surgery

Start date: March 2008
Phase: N/A
Study type: Interventional

Pleth Variability Index (PVI) seems to be an ideal parameter to guide fluid management: dynamic parameter and non-invasive. PVI could guide fluid management during surgery and optimization of the plethysmographic-derived parameter could improve hemodynamics of the patients.

NCT ID: NCT00813709 Completed - Multiple Sclerosis Clinical Trials

Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX)

REFLEXION
Start date: December 2008
Phase: Phase 3
Study type: Interventional

REFLEXION is a double blind extension of the study 27025 (NCT00404352) (REFLEX). The purpose of the study is to obtain long-term follow-up data in subjects with clinically definite multiple sclerosis (MS) and subjects with a first demyelinating event at high risk of converting to MS, treated with fetal bovine serum [FBS]-free/human serum albumin [HSA]-free formulation of interferon [IFN]-beta-1a (RNF).

NCT ID: NCT00813046 Completed - Clinical trials for Seasonal Allergic Rhinoconjunctivitis

Safety and Tolerance Study of Grass Pollen-derived Peptides to Treat Allergic Rhinitis

Start date: December 2008
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine whether the oral administration of grass pollen peptides to treat allergic rhinitis is safe and well tolerated.

NCT ID: NCT00812825 Completed - Healthy Volunteers Clinical Trials

A Phase 1 Multiple-Dose Escalation and Single Dose (Tablet) Study of PF-04171327 in Healthy Volunteers

Start date: January 2009
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the safety, tolerability, pharmacokinetics and pharmacodynamics (how the drug effects certain target sites of activity in the body) of escalating doses of oral PF-04171327 in healthy volunteers for 14 days (Part 1). Part 2 will evaluate the pharmacokinetics of a single 10 mg dose of the PF-04171327 tablet in healthy volunteers.